

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 November 2003 (13.11.2003)

PCT


(10) International Publication Number
WO 03/092698 A1

- (51) International Patent Classification⁷: **A61K 31/55**, C07D 223/16, 405/12, 413/04 (74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).
- (21) International Application Number: PCT/EP03/04343 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 25 April 2003 (25.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: MI2002A000934 3 May 2002 (03.05.2002) IT (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **DINAMITE DIPHARMA S.P.A., in abbreviated form DIPHARMA S.P.A.** [IT/IT]; S.S. 13 Pontebbana 103, I-33031 Basiliano (IT).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): **CASTALDI, Graziano** [IT/IT]; Via Livia Gallina, 5, I-28072 Briona (IT). **RAZZETTI, Gabriele** [IT/IT]; Via G. Puccini, 60, I-20099 Sesto S. Giovanni (IT). **MANTEGAZZA, Simone** [IT/IT]; Via Stendhal 54, I-20144 Milano (IT).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/092698 A1

(54) Title: A PROCESS FOR THE PREPARATION OF BENAZEPRIL HYDROCHLORIDE



(57) Abstract: A process for the preparation of benazepril hydrochloride (2) starting from the Michael adduct (14), obtained reacting compounds of formula (11) and (13), as defined in the disclosure.


A PROCESS FOR THE PREPARATION OF BENAZEPRIL HYDROCHLORIDE

FIELD OF THE INVENTION

The present invention relates to antihypertensive agents, in particular ACE-inhibitors.


PRIOR ART

Benazepril (1), namely [S-(R*,R*)]3-[[1-(ethoxycarbonyl)-3-phenylpropyl]-amino]-2,3,4,5-tetrahydro-2-oxo-1-*H*-1-benzazepin-1-acetic]acid, is an antihypertensive compound belonging to the class of ACE-inhibitors, which are compounds inhibiting the angiotensine converting enzyme. Benazepril is usually employed in therapy in the form of hydrochloride (2).




The preparation of benazepril disclosed in US 4,410,520 and J. Med. Chem. 1985, 28, 1511-1516, reported in Scheme 1, involves the reductive amination of ethyl 2-oxo-4-phenyl butyrate (3) with (3S)-3-amino-1-carboxymethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (4) promoted by sodium cyanoborohydride. The two resulting benazepril isomers are obtained in a 7:3 diastereomeric ratio. Following treatment with hydrochloric acid gas and recrystallization, the hydrochloride is isolated in a 95:5 diastereomeric ratio and in 25% yield. The main drawback of this method is that it requires the use of sodium cyanoborohydride, which is a toxic reagent, and furthermore it affords the hydrochloride in too low a diastereomeric ratio to be marketed.

Scheme 1



US 4,410,520 discloses other methods for the preparation of benazepril,
 5 as reported in Scheme 2, which however make use of precursors difficult to
 obtain and afford diastereomeric mixtures difficult to separate.


Scheme 2



An alternative method to those reported above was disclosed in EP 206993. It involves the nucleophilic substitution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**11**), using N-methylmorpholine as solvent/reagent, on the chiral substrate ethyl (2R)-2-(4-nitrobenzenesulfonyl)-4-phenyl butyrate (**10**) which is in turn prepared starting from ethyl 2-oxo-4-phenyl butyrate (**3**), by stereoselective hydrogenation in the presence of chiral bases (e.g. cinchonidine) (scheme 3), which step makes the whole process rather complex. The reaction between compounds (**10**) and (**11**) is carried out at 80°C for more than 6 hours.

10 Treatment with hydrochloric acid gas and precipitation with ethyl acetate directly afford Benazepril hydrochloride in a S,S:R,S = 99.7:0.3 diastereomeric ratio.

Scheme 3



DETAILED DISCLOSURE OF THE INVENTION


The present invention relates to a process for the preparation of benazepril hydrochloride, reported in Scheme 4, which makes use of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one

5 (11) as a precursor.

The process comprises the following steps:

- a) reacting (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (11) with a 3-benzoyl acrylic acid ester (13) to give the corresponding Michael adduct (14);
- 10 b) transforming the adduct (14) to give 3-[[1-(carboxy)-3-phenyl-propyl]-amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15);
- c) crystallizing the S,S isomer of compound (15);
- d) esterifying compound (15) to give 3-[[1-(ethoxycarbonyl)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-
15 benzazepin-2-one (12);
- e) treating compound (12) with hydrochloric acid gas to give benazepril hydrochloride.

Scheme 4



In compounds of formula (13) and (14) R is a straight or branched
 5 C₁-C₆ alkyl group or a benzyl group.

Step a) is carried out reacting compound (11) with compounds (13) in
 molar amounts ranging from 0.5 to 2, preferably from 0.9 to 1.1, in organic
 solvents selected for example from aromatic solvents, preferably toluene,
 chlorinated solvents, preferably dichloromethane, esters, preferably ethyl
 10 acetate, ethers, preferably diethyl ether and tetrahydrofuran, dipolar aprotic
 solvent, preferably dimethylformamide, aliphatic solvents, preferably
 cyclohexane, alcohols, preferably methanol, ketones, preferably acetone.
 According to preferred embodiments of the invention, the reaction is carried
 out in toluene or in ethyl acetate, most preferably in toluene. The reaction is

carried out at temperatures ranging from -10°C to 80°C, preferably from 0°C to 25°C. Compounds (14) are obtained in high yields and consist of a mixture of two S,S and S,R diastereomers, in a ratio which mainly depends on the solvent used, as reported in Table 1 for compound (14a), in which R is ethyl
5 (obtained in a yield higher than 95%). The best results are obtained with apolar solvents such as toluene.

Table 1: Relationship between solvent - (14a) diastereomer ratio


Solvent	14a (R=C ₂ H ₅) S,S/S,R isomers ratio
Dichloromethane	65:35
Toluene	75:25
Dimethylformamide	60:40
Methanol	58:42
Ethyl acetate	60:40
Ethyl acetate under reflux	40:60
Cyclohexane	73:27
Water	No reaction
Hexane	No reaction

The Michael adduct (14) is a novel compound and is also part of the
10 present invention.

The transformation of step b) can be carried out as follows:

b1) compound (14) is hydrogenated in the same solvent as used for step a) in the presence of a catalyst selected for example from Pd, Pt, Rh, Ru, Cu, in molar amounts ranging from 0.01 to 1, preferably from 0.01 to 0.1, on
15 supports selected for example from charcoal, alumine, barium sulfate, calcium carbonate, at temperatures ranging from -10°C to 80°C, preferably from 0°C to 30°C, at a hydrogen pressure ranging from 1 atm to 40 atm, preferably from 2 atm to 10 atm, to give a compound of formula (16), in which R has the meanings as defined above (scheme 5). According to a preferred embodiment
20 of the invention, the reaction is carried out without isolating compound (14), using ethyl acetate or toluene as solvent, preferably toluene, and Pd on charcoal as catalyst.

Scheme 5




5 The resulting intermediate (**16**) consists of a mixture of four diastereomers (SSS, SRS, SSR, SRR); this compound is also novel and it forms part of the invention.

Transformation into (**15**) is completed preferably without isolating compound (**16**), but treating the mixture from the above reaction with a
 10 mineral or organic acid and carrying out the catalytic reduction as described above. The mineral acid is preferably sulfuric acid, while the organic acid is preferably selected from acetic acid, trifluoroacetic acid, methanesulfonic acid and toluenesulfonic acid, more preferably acetic acid.

b2) Compound (**14**) is hydrogenated to compound (**16**) as described in
 15 b1. The catalyst is filtered off, then the solution containing (**16**) is added with acetic acid in molar ratios ranging from 0.1 to 100 with respect to (**16**) and left to react at temperatures ranging from 0 to 120°C, preferably from 15 to 60°C. The resulting lactone (**17**) is a novel compound and is also part of the present invention.

Scheme 6




Similarly to the parent compound (16), compound (17) consists of a diastereomeric mixture (SSS, SSR, SRR, SRS). Transformation of (17) into (15) can be carried out by catalytic hydrogenation under the same conditions as used to transform (14) into (16) or by "hydrogen transfer" reaction. Particularly useful hydrogen donors are cyclic ethers, cyclohexene, cyclohexadiene, methylcyclohexene, limonene, dipentene, mentene, hydrazine, phosphinic acid and derivatives, indoline, ascorbic acid, formic acid and the sodium or ammonium salts thereof, secondary alcohols such as isopropanol, in molar ratios from 1.5 to 50, preferably from 1.5 to 10. The use of cyclohexene in molar ratios from 1.5 to 3 or ammonium formate in molar ratios from 1 to 4 is preferred, in particular the latter one.

b3) Compound (14) is treated with sodium borohydride in molar ratios from 0.25 to 5, preferably from 0.5 to 1.5, at temperatures from 0 to 80°C, preferably from 10 to 30°C. If necessary, sodium borohydride may be dissolved by addition of methanol as cosolvent, or the reactive can be dissolved in a 0.1 M NaOH solution, subsequently adding a phase transfer

catalyst such as tetrabutylammonium chloride. This reaction directly affords lactone (17), which is transformed into (15) as described in b2 (scheme 7).

Scheme 7



The resulting compound (15), consisting of a S,S and S,R diastereomeric mixture, is crystallized (step c) by treatment with an organic solvent selected from an aromatic solvent, preferably toluene, a chlorinated solvent, preferably dichloromethane, an ester, preferably ethyl acetate, an ether, preferably diethyl ether and tetrahydrofuran, a dipolar aprotic solvent, preferably dimethylformamide, an aliphatic solvent, preferably cyclohexane, an alcohol, preferably methanol or isopropanol, a ketone, preferably acetone, or a mixture thereof, either alone or with acetic acid, more preferably with dichloromethane, methanol or isopropanol or a mixture of acetone and glacial acetic acid; and thus enriched in the S,S isomer (the S,S:S,R ratio being higher than 95:5).


10 15

Step d) is carried out reacting compound (15) with carbonyldiimidazole in molar amounts ranging from 0.5 to 2, preferably from 0.9 to 1.2, in one of the same solvents as indicated for step a) except alcohols, at temperatures ranging from -10°C to 80°C, preferably from 0°C to 25°C. According to a preferred embodiment of the invention, the solvent is toluene. The reaction of compound (15) with carbonyldiimidazole affords two reactive species (scheme 8). A small percentage consists of imidazolide (18), which is usually obtained by reaction of carbonyldiimidazole with a carboxylic acid, while the main part

20 25

consists of the activated heterocyclic compound (19), as evidenced by HPLC and NMR analysis of the mixture.

Scheme 8




After completion of the conversion of compound (15) into the two reactive species, ethanol is added to the reaction mixture which is left under stirring until complete disappearance of intermediates (18) and (19) (HPLC and NMR analysis). After evaporation of the solvents at reduced pressure, the residue is taken up with the same reaction solvent, then washed with water and the organic phase is evaporated to dryness. The resulting crude is subjected to the subsequent step.

Step e) is carried out with known methods. Preferably, the crude from step d) is dissolved in ethyl acetate and hydrochloric acid gas is bubbled therein at temperatures ranging from -10 to 10°C. After completion of the precipitation of benazepril hydrochloride, the residual hydrochloric acid is removed with conventional methods, after that the product is crystallized from acetone. Benazepril hydrochloride is obtained with diastereomeric purity above 99%.

The process of the present invention can also be conveniently carried out directly reacting intermediate of formula (16) in which R is ethyl (16a), obtained as described in b1 or in b2, with carbonyldiimidazole, in one of the solvents selected from those as indicated at step d), to give ethyl 3-(1-t-butoxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-2-oxo-6-phenyl-[1,3]oxazinan-4-carboxylate (20), as a mixture of the four possible diastereomers (SSS, SSR, SRS, SRR). Compound (20) is a novel compound and it forms part of the present invention. According to this variation, illustrated in Scheme 9, step e) comprises reaction with carbonyldiimidazole, then hydrogenation of compound (20) under the same conditions as indicated for step b) to give compound (12) as a S,S and S,R diastereomeric mixture. According to a preferred embodiment of the invention, step d) is carried out without isolating compound (16a), but filtering off the catalyst from the reaction mixture and adding carbonyldiimidazole. Analogously, compound (20) is not isolated from the mixture and, after addition of the catalyst, is directly subjected to catalytic hydrogenation.

Scheme 9



Afterwards, step f) is carried out as described above.

5 The invention is illustrated in further detail by the following examples.

Examples

Example 1: preparation of 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxy-carbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15)

Ethyl 3-benzoylacrylate (13a) (55.6 g, 272 mmoles) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (11) (66.2 g, 228 mmoles) in 200 ml of ethyl acetate, at room temperature in 1h. The resulting mixture is left under stirring for 18h, added with 10% Pd-C (26 g, 22 mmoles) and hydrogenated at 3 atm for 18h at room temperature. After completion of the reaction, 200 ml of acetic acid are added and the mixture is hydrogenated for a further 18h at 3 atm and at room temperature. After this time, the catalyst is filtered off through Celite and the solvent mixture is evaporated to dryness, the residue is taken up in dichloromethane (200 ml) and the resulting precipitate is filtered, washed with 20 ml of dichloromethane and dried to give 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-

2-one (**15**) (36 g, yield: 32%).

¹H-NMR (CDCl₃, δ in ppm): 1.42 (s, 9H), 2.03 (m, 3H), 2.38 (m, 1H), 2.57 (dd, 1H), 2.75 (m, 2H), 3.07 (t, 1H), 3.23 (m, 2H), 4.32 (d, 1H), 4.57 (d, 1H), 7.05-7.40 (aromatics, 9H).

5 **Example 2: preparation of 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**15**)**

Ethyl 3-benzoylacrylate (**13a**) (55.6 g, 272 mmol) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**11**) (66.2 g, 228 mmol) in 200 ml of toluene, at room
10 temperature in 1h. The resulting mixture is left under stirring for 18h, added with 10% Pd-C (26 g, 22 mmol) and hydrogenated at 3 atm for 18h at room temperature. After completion of the reaction, 200 ml of acetic acid are added and the mixture is hydrogenated for a further 18h, at 3 atm at room temperature, after that the catalyst is filtered off through Celite and the solvent
15 mixture is evaporated to dryness. The residue is taken up with isopropanol (500 ml) and the resulting precipitate is filtered, washed with 20 ml of dichloromethane and dried to give 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**15**) (58.5 g, yield: 52%).

20 **Example 3: preparation of 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**15**)**

Ethyl 3-benzoylacrylate (**13a**) (55.6 g, 272 mmol) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**11**) (66.2 g, 228 mmol) in 200 ml of toluene, at room
25 temperature in 1h. The resulting mixture is left under stirring for 18h, then added with 10% Pd-C (26 g, 22 mmol) and hydrogenated at 3 atm for 18h at room temperature. After completion of the reaction the catalyst is filtered off through Celite, 50 ml of acetic acid are added and the solvent mixture is

evaporated to kettle temperature of 110-120°C. The residue is taken up in 200 ml of toluene, 50 ml of acetic acid then cyclohexene (50 ml) and 10% Pd-C (26 g, 22 mmoles) are added. The reaction mixture is heated to 80°C for 18h, after that the catalyst is filtered off through Celite and solvents are evaporated
5 off. The residue is taken up with isopropanol (500 ml) and the resulting precipitate is filtered, washed with 20 ml of isopropanol and dried to give 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15) (60.7 g, yield: 54%).

Example 4: preparation of 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15)
10

Ethyl 3-benzoylacrylate (13a) (55.6 g, 272 mmoles) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (11) (66.2 g, 228 mmoles) in 200 ml of toluene, at room temperature in 1h. The resulting mixture is left under stirring for 18h, then a
15 solution of sodium borohydride (228 mmoles 8.6 g) and tetrabutylammonium chloride (5.0 g) in 50 ml of 0.1 M NaOH is added and the mixture is stirred at room temperature for 18h. The aqueous phase is separated, 50 ml of acetic acid are added to the organic phase and the mixture is left under stirring for 30', then added with 10% Pd-C (26 g, 22 mmoles) and ammonium formate
20 (456 mmoles, 33.3 g) and left under stirring for 4h. Afterwards, the catalyst is filtered off through Celite and 100 ml of water is added. The resulting precipitate is filtered, washed with 20 ml of isopropanol and dried to give 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15) (53.9 g, yield: 48%).

Example 5: preparation of benazepril hydrochloride (2)
25

25 g (55.2 mmoles) of 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonyl-methyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15) are suspended in 250 ml of toluene and added with carbonyldiimidazole (10.74 g,

66.2 mols). The mixture is left under stirring for 2h, then 100 ml of ethanol are added. After reacting for 4h, solvents are evaporated off and the residue is taken up with 300 ml of toluene and 100 ml of water. The phases are separated and the organic phase is washed twice with water. Toluene is then evaporated
5 off and the mixture is taken up with 75 ml of ethyl acetate, cooled to 10°C and HCl gas is bubbled therein. After precipitation of the product, about 2/3 of the solvent are distilled off twice, adding each time fresh solvent to remove the residual HCl, then the mixture is diluted with 75 ml of acetone, cooled to 10°C and filtered, to obtain 21.4 g of product (84% yield).

10 ¹H NMR (D₂O, δ in ppm): 1.02 (t, 3H), 2.17 (m, 3H), 2.43 (m, 1H), 2.61 (m, 3H), 2.97 (m, 1H), 3.77 (m, 2H), 3.97 (q, 2H), 4.36 (d, 1H), 4.57 (d, 1H), 7.05-7.35 (aromatics, 9H).

Example 6: preparation of benazepril hydrochloride (2)

Ethyl 3-benzoylacrylate (**13a**) (55.6 g, 272 mmols) is dropped into a
15 solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**11**) (66.2 g, 227 mmols) in 200 ml of toluene, at room temperature in 1h. The resulting mixture is left under stirring for 18h, then added with 10% Pd-C (26 g, 22 mmols) and hydrogenated at 3 atm for 18h at room temperature. The catalyst is filtered off and carbonyldiimidazole (272
20 mmols, 44.2 g) is added. After reacting for 4h the mixture is washed 3 times with 100 ml of water, added again with 10% Pd-C (26 g, 22 mmols) and hydrogenated at 1 atm for 18h at room temperature. After that the catalyst is filtered off, the solvent is evaporated off and the residue is taken up with 240 ml of ethyl acetate, cooled to 10°C and HCl gas is bubbled therein to complete
25 precipitation of the product. About 2/3 of the solvent is distilled off twice, adding each time fresh solvent to remove the residual HCl. The mixture is then diluted with 75 ml of acetone, cooled to 10°C and filtered, to obtain 32 g of product (31% yield).

¹H NMR (D₂O, δ in ppm): 1.02 (t, 3H), 2.17 (m, 3H), 2.43 (m, 1H), 2.61 (m, 3H), 2.97 (m, 1H), 3.77 (m, 2H), 3.97 (q, 2H), 4.36 (d, 1H), 4.57 (d, 1H), 7.05-7.35 (aromatics, 9H).

Example 7: preparation of 3-[[1-(ethoxycarbonyl)-3-oxo-3-phenyl-propyl]-amino]-1-t-butyl-oxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (14)

Ethyl 3-benzoylacrylate (13a) (55.6 g, 272 mmol) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (11) (66.2 g, 227 mmol) in 200 ml of toluene, at room temperature in 1h. The resulting mixture is left under stirring for 18h, then solvent is evaporated off and the residue is purified by chromatography (eluent hexane-ethyl acetate 7:3). Two isomeric products are isolated.

Isomer 1 (first eluted) – minor product (SR):

¹H-NMR (CDCl₃, δ in ppm): 1.17 (t, 3H), 1.40 (s, 9H), 1.92 (m, 1H), 2.30 (m, 1H), 2.55 (dd, 1H), 3.32 (m, 4H), 3.72 (t, 1H), 4.08 (q, 2H), 4.23 (d, 1H), 4.66 (d, 1H), 7.05-8.00 (aromatics, 9H).

Isomer 2 (second eluted) – main product (SS):

¹H-NMR (CDCl₃, δ in ppm): 1.05 (t, 3H), 1.40 (s, 9H), 1.98 (m, 1H), 2.38 (m, 1H), 2.57 (dd, 1H), 3.35 (m, 4H), 3.64 (t, 1H), 4.02 (q, 2H), 4.24 (d, 1H), 4.53 (d, 1H), 7.05-8.00 (aromatics, 9H).

Example 8: preparation of 3-[[1-(ethoxycarbonyl)-3-hydroxy-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (16)

Ethyl 3-benzoylacrylate (13a) (55.6 g, 250 mmol) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (11) (66.2 g, 227 mmol) in 200 ml of toluene, at room temperature in 1h. The resulting mixture is left under stirring for 18h, then added with 10% Pd-C (26 g, 22 mmol) and hydrogenated at 3 atm for 18h at

room temperature. The solvent is evaporated off and the residue is purified by chromatography (eluent: hexane-ethyl acetate 7:3). A mixture of isomeric products is isolated.

¹H-NMR (CDCl₃, δ in ppm): 1.03-1.32 (m, 3H), 1.40 (m, 9H), 1.73-1.93 (m, 1H), 1.95-2.15 (m, 1H), 2.38 -2.63 (m, 2H), 3.18-3.43 (m, 4H), 3.98-4.12 (m, 2H), 4.25-4.60 (m, 2H), 4.68-5.20 (m, 1H), 7.05-7.40 (aromatics, 9H).

Example 9: preparation of ethyl 3-(1-t-butoxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)2-oxo-6-phenyl-[1,3]oxazinan-4-carboxylate (20)

Ethyl 3-benzoylacrylate (**13a**) (55.6 g, 250 mmol) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**11**) (66.2 g, 227 mmol) in 200 ml of toluene, at room temperature in 1h. The resulting mixture is left under stirring for 18h, then added with 10% Pd-C (26 g, 22 mmol) and hydrogenated at 3 atm for 18h at room temperature. The catalyst is filtered off and carbonyldiimidazole (272.4 mmol, 44.16 g) is added. After reacting for 4h the mixture is washed 3 times with 100 ml of water. After completion of the reaction the solvent is evaporated off and the residue is purified by chromatography (eluent: hexane-ethyl acetate 7:3). A mixture of isomeric products is isolated.

¹H-NMR (CDCl₃, δ in ppm): 1.03-1.32 (m, 3H), 1.40 (m, 9H), 1.83-2.40 (m, 5H), 3.05-3.37 (m, 3H), 3.95-4.08 (m, 2H), 4.17-4.62 (m, 2H), 5.90-6.20 (m, 1H), 7.05-7.40 (aromatics, 9H).

Example 10: preparation of [2-oxo-3-(2-oxo-5-phenyl-tetrahydro-furan-3-ylamino)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-acetic acid tert-butyl ester (17)

Ethyl 3-benzoylacrylate (**13a**) (55.6 g, 250 mmol) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (**11**) (66.2 g, 227 mmol) in 200 ml of toluene, at room

temperature in 1h. The resulting mixture is left under stirring for 18h, then added with 10% Pd-C (26 g, 22 mmoles) and hydrogenated at 3 atm for 18h at room temperature. After completion of the reaction, the catalyst is filtered off, 50 ml of acetic acid are added and volatiles are distilled off at 110-120°C
5 inner temperature.

The residue is purified by chromatography (eluent: hexane-ethyl acetate 7:3) to obtain a mixture of isomeric products.


¹H-NMR (CDCl₃, δ in ppm): 1.45 (m, 9H), 1.82-2.15 (m, 2H), 2.41 -2.63 (m, 3H), 3.18-3.43 (m, 1H), 3.18-3.95 (m, 2H), 4.25-4.60 (m, 2H), 5.15-5.70 (m,
10 1H), 7.05-7.40 (aromatics, 9H).

Example 11: preparation of 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15)

Ethyl 3-benzoylacrylate (13a) (55.6 g, 272 mmoles) is dropped into a solution of (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-
15 benzazepin-2-one (11) (66.2 g, 228 mmoles) in 200 ml of toluene, at room temperature in 1h. The resulting mixture is left under stirring for 18h, then added with 10% Pd-C (26 g, 22 mmoles) and hydrogenated at 3 atm for 18h at room temperature. After completion of the reaction the catalyst is filtered off through Celite, 100 ml of acetic acid are added and the solvent mixture is
20 reacted at 20-30°C for 18h. After lactonization to compound (17), ammonium formate (51.4 g, 816 mmoles) and 10% Pd-C (26 g, 22 mmoles) are added. The reaction mixture is heated to 40°C for 3h, after that the catalyst is filtered off through Celite and solvents are evaporated off. The residue is taken up with acetone (600 ml) and acetic acid (200 ml), heated to dissolution and cooled. The
25 resulting precipitate is filtered, washed with 80 ml of acetone and dried to give 3-[[1-(carboxy)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15) (60.7 g, yield: 54%).

CLAIMS


1. A process for the preparation of benazepril hydrochloride (2),



2


comprising the following steps:

- a) reacting (3S)-3-amino-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (11)



11


with a 3-benzoyl acrylic acid ester (13)



13

in which R is a straight or branched C₁-C₆ alkyl group or a benzyl group,


to give a Michael adduct of formula (14)




14

in which R has the meanings as defined above;

b) transforming compound (14) into 3-[[1-(ethoxycarbonyl)-3-hydroxy-3-phenyl-propyl] amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (15)



c) crystallizing the S,S isomer of compound (15);
 d) esterifying compound (15) to give 3-[[1-(ethoxycarbonyl)-3-phenyl-propyl]amino]-1-t-butoxycarbonylmethyl-2,3,4,5-tetrahydro-1H-benzazepin-2-one (12); and



e) treating compound (12) with hydrochloric acid gas to give benazepril hydrochloride (2).


2. A process as claimed in claim 1 wherein R is ethyl.

3. A process as claimed in claim 1 or 2 wherein step b) is carried out without isolating compound (14).

4. A process according to any one of the above claims wherein step b) comprises:

catalytic hydrogenation of compound (14) to give an intermediate of formula (16)

21




in which R has the meanings as defined above; and
catalytic hydrogenation of compound (16) in the presence of a mineral or organic acid to give compound (15).

- 5 5. A process as claimed in claim 4 wherein the mineral acid is sulfuric acid and the organic acid is acetic acid.
6. A process as claimed in any one of claims 1-3 wherein step b) comprises:

catalytic hydrogenation of compound (14) to give compound (16);


- 10 conversion of compound (16) to lactone (17); and



conversion of compound (17) to compound (15) by catalytic hydrogenation or by hydrogen transfer reaction.





- 15 7. A process as claimed in claim 6 wherein compound (16) is converted to lactone (17) by addition of acetic acid and heating to a temperature ranging from 0°C to 120°C.
8. A process as claimed in claim 6 wherein compound (14) is directly converted to lactone (17) by reduction with sodium borohydride.
- 20 9. A process as claimed in claim 4 wherein the catalyst is Pd supported on charcoal.

10. A process as claimed in any one of claims 6 or 7 wherein the hydrogen transfer reaction comprises the use of a hydrogen donor selected from cyclic ethers, cyclohexene, cyclohexadiene, methylcyclohexene, limonene, dipentene, mentene, hydrazine, phosphinic acid and derivatives, indoline, ascorbic acid, formic acid and the sodium or ammonium salts thereof, secondary alcohols.
11. A process as claimed in claim 10 wherein the hydrogen donor is ammonium formate.
12. A process as claimed in claim 1, wherein step c) crystallization is carried out in a mixture of acetone and acetic acid, as solvent.
13. A process as claimed in claim 1 wherein steps a) and b) are carried out in a solvent selected from toluene, dichloromethane, ethyl acetate, diethyl ether, tetrahydrofuran, dimethylformamide, cyclohexane, methanol and acetone, and step d) is carried out in a solvent selected from toluene, dichloromethane, ethyl acetate, diethyl ether, tetrahydrofuran, dimethylformamide, cyclohexane and acetone.
14. A process as claimed in claim 13, wherein the solvent is toluene.
15. A process as claimed in claim 1 wherein step d) is carried out reacting compound (15) with carbonyldiimidazole and ethanol.
16. A process as claimed in any one of claims 4-7 wherein compound (16) in which R is ethyl is treated with carbonyldiimidazole to give ethyl 3-(1-t-butoxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-2-oxo-6-phenyl-[1,3]oxazinan-4-carboxylate (20)



which is subjected to catalytic reduction to give compound (12).

17. A process according to any one of the above claims wherein the catalytic reductions or hydrogen transfer reactions are carried out in the presence of a catalyst selected from Pd, Pt, Rh, Ru, Cu on a support selected from charcoal, alumine, barium sulfate, calcium carbonate.
- 5 18. A process as claimed in claim 16 wherein the catalytic reduction is carried out without isolating compound (20).
19. A compound selected from the group consisting of:



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/04343

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/55 C07D223/16 C07D405/12 C07D413/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, CHEM ABS Data, EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 206 993 A (CIBA GEIGY AG) 30 December 1986 (1986-12-30) cited in the application page 9, paragraph 2 -page 10, paragraph 1 -----	1, 19
A	US 4 410 520 A (WATTHEY JEFFREY W H) 18 October 1983 (1983-10-18) cited in the application column 9, line 15 -column 15, line 39 -----	1, 19
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 18 July 2003		Date of mailing of the international search report 25/07/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Fanni, S

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/04343

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0206993	A	30-12-1986	AT 53014 T 15-06-1990
			CA 1338089 C 27-02-1996
			CY 1710 A 14-01-1994
			DD 266097 A5 22-03-1989
			DD 283611 A5 17-10-1990
			DE 3671439 D1 28-06-1990
			DK 39695 A 07-04-1995
			DK 170277 B1 24-07-1995
			EP 0206993 A1 30-12-1986
			ES 8801197 A1 01-03-1988
			ES 8802013 A1 01-06-1988
			FI 862462 A , B, 14-12-1986
			HK 63293 A 09-07-1993
			HU 203074 B 28-05-1991
			IE 58477 B1 22-09-1993
			IL 79077 A 25-01-1994
			JP 1858073 C 27-07-1994
			JP 5067140 B 24-09-1993
			JP 61289073 A 19-12-1986
			JP 2092904 C 18-09-1996
			JP 5310656 A 22-11-1993
			JP 7035358 B 19-04-1995
			KR 9407529 B1 19-08-1994
			PT 82744 A , B 01-07-1986
			SG 32393 G 21-05-1993
			US 5066801 A 19-11-1991
			US 4785089 A 15-11-1988
US 4410520	A	18-10-1983	US 4473575 A 25-09-1984
			AT 18397 T 15-03-1986
			AU 561395 B2 07-05-1987
			AU 8701482 A 12-05-1983
			CA 1196636 A1 12-11-1985
			CY 1403 A 18-12-1987
			DD 202546 A5 21-09-1983
			DE 3269625 D1 10-04-1986
			DK 358682 A , B, 12-02-1983
			EP 0072352 A1 16-02-1983
			ES 8502974 A1 01-05-1985
			ES 8601142 A1 16-02-1986
			ES 8606285 A1 01-10-1986
			ES 8504728 A1 16-07-1985
			ES 8604523 A1 01-07-1986
			ES 8602682 A1 16-03-1986
			FI 822770 A , B, 12-02-1983
			GB 2103614 A , B 23-02-1983
			GR 77256 A1 11-09-1984
			HK 93387 A 18-12-1987
			HU 189628 B 28-07-1986
			IE 53668 B1 04-01-1989
			IL 66501 A 20-10-1987
			KR 8903425 B1 20-09-1989
			KR 9001190 B1 28-02-1990
			KR 9001191 B1 28-02-1990
			NO 822722 A , B, 14-02-1983
			NZ 201555 A 11-06-1986
			PT 75395 A , B 01-09-1982